|
|
|
|
| LEADER |
01370nam a2200265 u 4500 |
| 001 |
EB001840365 |
| 003 |
EBX01000000000000001004354 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Mepolizumab (Nucala)
|h Elektronische Ressource
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 2016 Nov
|
| 300 |
|
|
|a 1 online resource
|b illlustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Asthma / drug therapy
|
| 653 |
|
|
|a Adrenergic beta-2 Receptor Agonists / therapeutic use
|
| 653 |
|
|
|a Eosinophils / drug effects
|
| 653 |
|
|
|a Adrenergic beta-2 Receptor Agonists / adverse effects
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK409875
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and one or more additional asthma controllers
|